The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 21, No. 2, pp. 167-172.
© 1987 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berg, M.
Right arrow Articles by Schottelius, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berg, M.
Right arrow Articles by Schottelius, D.

Research Articles

Parkinsonism--drug treatment: Part II

MJ Berg, B Ebert, DK Willis, T Host, RW Fincham, and DD Schottelius

This article, second in a two-part review, discusses investigational drug therapy and miscellaneous drug management of parkinsonism. Drug therapy should be individualized according to signs and changed as the disease progresses or if the patient develops intolerable side effects. Investigational drugs being examined include sustained-release and injectable dopaminergic formulations. Drug-induced parkinsonism is also examined.


This article has been cited by other articles:


Home page
 NeurologyHome page
D. L. Gilbert, G. Sethuraman, L. Sine, S. Peters, and F. R. Sallee
Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial
Neurology, March 28, 2000; 54(6): 1310 - 1315.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1987 by Harvey Whitney Books Company.